Clin2
NCT07432958Likely a fitRecruiting

Study of AP-472 with levodopa for Parkinson's motor fluctuations

Parkinson Disease

Part of Brain & nervous system clinical trials.

This trial tests an experimental drug called AP-472, taken alongside your regular Parkinson's medications, to see if it can reduce the amount of "OFF" time you experience each day when symptoms return between doses of levodopa.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
150 people
Ages
30 years to 80 years
Study type
Interventional

Who can take part

  • You are between 30 and 80 years old.
  • You have been diagnosed with typical Parkinson's disease (not other forms of parkinsonism).
  • You experience at least 3 hours of "OFF" time per day when Parkinson's symptoms return.
  • You are able to walk on your own or with a walking aid.
  • You have been on a stable dose of your Parkinson's medications for at least 4 weeks, and MAO-B inhibitors for 12 weeks.
  • You take levodopa at least 4 times a day for immediate-release or 3 times a day for extended-release formulations.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07513441Recruiting· Phase 1
Testing Lu AF28996 for Parkinson's disease motor fluctuations

This early-stage trial tests a new medication called Lu AF28996 in Chinese patients with Parkinson's disease who experience predictable on-off episodes (times when medication works well versus poorly). The study aims to see if this drug can help reduce those difficult off periods.

Beijing, Beijing Municipality
NCT04735627Recruiting
Real-time monitoring of levodopa levels in Parkinson’s

This study checks whether measuring levodopa (a Parkinson medicine) in real time can help better understand Parkinson medication effects. You may be asked to wear/perform study monitoring while taking your usual carbidopa/levodopa tablets.

San Diego, California
NCT07280299Not yet recruiting· Phase 2
Study of GT-02287 for early Parkinson's disease

This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.

NCT07145190Recruiting
Starting Sublingual Apomorphine for Parkinson's OFF Episodes

This study looks at how patients start and adjust a new medicine (sublingual apomorphine, or SL-APO) for Parkinson's disease OFF episodes. OFF episodes are times when Parkinson's symptoms come back between medicine doses. If you are about to start SL-APO for the first time, this trial may be a good fit.

Berlin
NCT06732180Recruiting· Phase 1
Testing a new drug (GT-02287) for Parkinson's disease

This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.

Darlinghurst, New South Wales
NCT07138560Recruiting· Phase 4
Study of IPX-203 for Parkinson's disease (BOOST-PD)

This study tests a new formulation of carbidopa-levodopa (IPX-203) to see how well it works for people with Parkinson's disease. It uses a wearable device to measure movement and aims to improve “off” time, when symptoms return between doses.

Cleveland, Ohio

Hear when a new Parkinson Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.